OPTIMIZATION, CHARACTERIZATION AND IN VIVO STUDY OF RIVASTIGMINE TARTRATE NANOPARTICLES BY USING 22 FULL FACTORIAL DESIGN FOR ORAL DELIVERY

NEHA DUBEY; OM PRAKASH AGRAWAL; BINA GIDWANI

doi:10.22159/ijap.2023v15i3.47140

Authors

NEHA DUBEY Columbia Institute of Pharmacy, Tekari, Raipur, Chhattisgarh, India https://orcid.org/0000-0001-5798-968X
OM PRAKASH AGRAWAL RKDF College of Pharmacy, Sarvepalli Radhakrishnan University, Misrod, Bhopal, Madhya Pradesh India
BINA GIDWANI Columbia Institute of Pharmacy, Tekari, Raipur, Chhattisgarh, India https://orcid.org/0000-0003-1257-723X

DOI:

https://doi.org/10.22159/ijap.2023v15i3.47140

Keywords:

Alzheimer’s disease, Rivastigmine tartrate, Solid lipid nanoparticles, Microemulsion cooling technique

Abstract

Objective: This research aims to optimize the solid lipid nanoparticles by using full factorial design to improve the delivery of rivastigmine tartrate (RT), which is used for the treatment of Alzheimer’s disease (AD). Solid lipid nanoparticles (SLNs) are attracting importance for drug developers due to their performance. The outcome of this research will lead to improvements in drug release and solubility of RT for better therapeutic effect.

Methods: Four different methods were used to prepare solid lipid nanoparticles of rivastigmine tartrate, namely the modified solvent emulsification technique, the microemulsion cooling technique, the solvent injection technique, and the homogenization/ultrasonication technique. Glyceryl monostearate (GMS) was used as a lipid; Compritol 888, tween 80, and span 40 were used as surfactants, co-surfactants, and stabilizers, respectively.

Results: SLNs were evaluated for zeta potential, particle size, polydispersity index, surface morphology, Fourier Transform Infrared Spectroscopy (FTIR), and differential scanning calorimetry (DSC). Entrapment efficiency and drug loading were also estimated. Solubility study of rivastigmine tartrate in different solid lipids as well as the in vitro drug release, was studied. The particle size of SLNs was found to range between 138.22+0.01 nm and 172.79+0.23 nm. The zeta potential of the optimized formulation was found to be in the the-24+0.01mV range, indicating a stable formulation. A scanning electron microscope indicates a clear spherical structure without any aggregation. Entrapment efficiency was determined to be 69.27+0.22%. The RT-SLNs showed significant retention in memory when compared with RT solution (standard formulation), which may be attributed to the lipid nature and nanostructure of the delivery system that may probably result in more accumulation of the drug in the brain to show better effect.

Conclusion: The current study concludes that the microemulsion cooling technique is the best method for patient compliance and stability with all desired characteristics parameters.

Downloads

Download data is not yet available.

References

Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci. 2015;78:54-66. doi: 10.1016/j.ejps.2015.07.002, PMID 26143262.

Talele P, Sahu S, Mishra AK. Physicochemical characterization of solid lipid nanoparticles comprised of glycerol monostearate and bile salts. Colloids Surf B Biointerfaces. 2018;172:517-25. doi: 10.1016/j.colsurfb.2018.08.067, PMID 30212689.

Ravi G, Gupta NV. Development of solid lipid nanoparticles of rivastigmine tartrate by using full factorial design for the treatment of Alzheimer’s disease. J Pharm Sci Res. 2017;9:2447-52.

Ravi G, Gupta NV. Development and evaluation of transdermal film containing solid lipid nanoparticles of rivastigmine tartrate. Int J App Pharm. 2017;9(6):85-90. doi: 10.22159/ijap.2017v9i6.22354.

Cunha S, Costa CP, Loureiro JA, Alves J, Peixoto AF, Forbes B. Double optimization of rivastigmine-loaded nanostructured lipid carriers (NLC) for nose-to-brain delivery using the quality by design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutics. 2020;12(7):599. doi: 10.3390/pharmaceutics12070599, PMID 32605177.

Wilson B, Geetha KM. Neurotherapeutic applications of nanomedicine for treating Alzheimer’s disease. J Control Release. 2020;325:25-37. doi: 10.1016/j.jconrel.2020.05.044, PMID 32473177.

Anand A, Arya M, Kaithwas G, Singh G, Saraf SA. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model. J Drug Deliv Sci Technol. 2019;49:219-26. doi: 10.1016/j.jddst.2018.11.021.

Swathi G, Prasanthi NL, Manikiran SS, Ramarao N. Solid lipid nanoparticles: colloidal carrier systems for drug delivery. ChemInform. 2012;43:121-45.

Nguyen TT, Maeng HJ. Pharmacokinetics and pharmacodynamics of intranasal solid lipid nanoparticles and nanostructured lipid carriers for nose-to-brain delivery. Pharmaceutics. 2022;14(3):572. doi: 10.3390/pharmaceutics14030572, PMID 35335948.

Ganesan P, Narayanasamy D. Lipid nanoparticles: different preparation techniques, characterization, hurdles, and strategies for the production of solid lipid nanoparticles and nanostructured lipid carriers for oral drug delivery. Sustain Chem Pharm. 2017;6:37-56. doi: 10.1016/j.scp.2017.07.002.

Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 1997;157(2):171-9. doi: 10.1016/s0378-5173(97)00222-6, PMID 10477814.

Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of acitretin-loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401(1-2):93-102. doi: 10.1016/j.ijpharm.2010.09.007, PMID 20858539.

Sharma A, Sood A, Mehta V, Malairaman U. Formulation and physicochemical evaluation of nanostructured lipid carrier for codelivery of clotrimazole and ciprofloxacin. Asian J Pharm Clin Res. 2016;1:356-60.

Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol. 2011;63(3):342-51. doi: 10.1111/j.2042-7158.2010.01225.x, PMID 21749381.

Salve P, Pise S, Bali N. Formulation and evaluation of solid lipid nanoparticle-based transdermal drug delivery system for Alzheimer’s disease. Rese Jour Pharmaceut Dosag Form and Technol. 2016;8(2):73-80. doi: 10.5958/0975-4377.2016.00011.2.

Tao C, Cheng H, Zhou K, Luo Q, Chen W. Preparation and characterization of biochanin A loaded solid lipid nanoparticles. Asian J Pharm (AJP). 2012;6:15-20.

Bhattacharjee S, Debnath R, Kumar SA, Saha A, Saha S, Debnath S. A technical review: solid-lipid nanoparticle (SLN), their characteristics and their preparation. Asian J Pharm Res Dev. 2020;8(3):185-9. doi: 10.22270/ajprd.v8i3.764.

Samein LH. Preparation and evaluation of nystatin loaded-solid-lipid nanoparticles for topical delivery. Int J Pharm Pharm Sci. 2014;1:592-7.

Craparo EF, Pitarresi G, Bondı ML, Casaletto MP, Licciardi M, Giammona G. A nanoparticulate drug-delivery system for rivastigmine: physico-chemical and in vitro biological characterization. Macromol Biosci. 2008;8(3):247-59. doi: 10.1002/mabi.200700165, PMID 18041108.

Anand A, Arya M, Kaithwas G, Singh G, Saraf SA. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model. J Drug Deliv Sci Technol. 2019;49:219-26. doi: 10.1016/j.jddst.2018.11.021.

Chauhan MK, Sharma PK. Optimization and characterization of rivastigmine nanolipid carrier-loaded transdermal patches for the treatment of dementia. Chem Phys Lipids. 2019;224:104794. doi: 10.1016/j.chemphyslip.2019.104794, PMID 31361985.

Soma D, Attari Z, Reddy MS, Damodaram A, Koteshwara KBG. Solid lipid nanoparticles of irbesartan: preparation, characterization, optimization and pharmacokinetic studies. Braz J Pharm Sci. 2017;53(1):5012. doi: 10.1590/s2175-97902017000115012.

Kulkarni AS, Chandrashekhar VB, Patil SR. Formulation and characterization of rivastigmine-loaded solid lipid nanoparticles. Int J Pharmres Scholars (IJPRS). 2018;7(1):30-41.

Arora D, Bhatt S, Kumar M, Verma R, Taneja Y, Kaushal N. QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer’s therapeutics. Front Aging Neurosci. 2022;14:960246. doi: 10.3389/fnagi.2022.960246. PMID 36034142.